drugset / Trial / NCT00324051

Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet

NCT00324051 ↗

Phase 4 Completed 284 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to estimate drug preference of stable schizophrenic patients who will be treated with olanzapine orodispersible tablets for 6 weeks then with olanzapine tablets for 6 weeks and vice-versa.

Timeline

Start
2006-05
Primary completion
2007-09
Completion
2007-09

Outcome

Met primary endpoint

paper 106 (61%) preferred ODT and 48 (27%) preferred OCT (P<0.001 adjusted for treatment sequence); PMID 20653494 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule — Oral

Indications